Climb Bio (CLYM) said Thursday it has signed an exclusive licensing deal with Beijing Mabworks Biotech to develop and commercialize anti-APRIL monoclonal antibody CLYM116 outside of Greater China to potentially treat patients with IgA nephropathy and other B-cell-mediated diseases.
Under the agreement, Climb Bio said it will pay $9 million upfront to Mabworks and make milestone payments as well as low- to mid-single-digit royalties on net sales outside of Greater China.
Climb Bio said it is conducting preclinical studies on CLYM116 and expects to share data later in 2025.
Additionally, the company said it had about $212.9 million in cash, cash equivalents and short-term marketable securities as of Dec. 31, which is expected to fund operations through 2027.
Price: 1.87, Change: -0.22, Percent Change: -10.53
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.